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In this study, the analytical and clinical performance
of six senistive TSH kits were evaluated. In the analytical
part, it was found that the detection limits of the kits
ranged from 0.02 mlUh to 0.18 mlUL. Except the Boots kit,
the coefficients of variation of the other assays at
different concentrations were below or around 10%. Although
the correlation of results between different kits were good
r=0.82 to 0.95) large discrepancies were found when aliquots
of the same control sera were assayed by different kits.
In the clinical part, the lower reference limits of TSH
assayed by the sensitive kits were around 0.3 to 0.4 mlUL,
0
much lower than the values obtained from conventional
radioimmunoassays. The upper limits were 3-4 mlUL. TSH
values in male and female subjects showed no significant
difference. They were also not age dependent. TSH results
from 35 overtly hyperthyroid patients, obtained from
different kits were all below the reference range. However,
suppressed TSH values were also found in 2 of the 71 healthy
subjects. In the successfully treated hyperthyroid patients,
suppressed TSH values occurred more frequently (19%).
Although a significant proportion of this group of patients
also had elevated T3 concentrations, they did not correlate
with the TSH concentrations( r -0.25) signifying that the
suppressed TSH values were not due to under-treatment.
This study also showed that during pregnancy, there were
significant changes in TSH and thyroid hormone
concentrations. Results obtained by the six sensitive TSH
kits showed that at least 25% of women in the first
trimester of pregancy had TSH values below the lower
reference limit. The mean value of TSH of the 26 pregnant
women at this gestational period was also significantly
lower than the reference mean (p0.01). In the second
trimester, the TSH suppression was less. In the third
trimester, the TSH concentrations returned to non-pregnant
values. The mean values of TT4, TT3 and FT3 increased by
53%, 67% and 59% respectively in the second trimester of
pregnancy. FTI was also increased during pregnancy but the
mean value in the first trimester was only 21% above the
reference mean. However, the FT4 values decreased
progressively during the course of pregnancy. By the time of
third trimester gestation, the mean value of FT4 was only 60%
of the reference mean.
Although the sensitivity of TSH for the detection of
hyperthyroidism is 100% when results were obtained by
sensitive assays, suppressed TSH values can also be found in
euthyroid subjects, pregnant women and many other conditions
unrelated to thyroid disorders, therefore, hyperthyroidism
cannot be diagnosed based on a suppressed TSH value.
However, a normal TSH value indicates that the pituitary is
not suppressed and hyperthyroidism can be excluded. Therefore
in most cases, a sensitive TSH assay can replace the TRH
stimulation test.
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The thyroid gland is an important endocrine gland which
is essential for normal body metabolism, mental development,
skeletal and sexual maturation. These physiological
functions are effected by the secretion of thyroid hormones,
thyroxine (T4) and triiodothyronine (T3). In a normal adult,
the thyroid gland secretes about 110 to 120 nmol of T4 and 10
to 20 nmol of T3 per day. In the peripheral tissues, about
30 to 40% of the plasma T4 undergoes B-deiodination to T3
and 30 to 40% undergoes -deiodination to reverse T3 r-
T3). Generally, over 70% of circulating T3 is derived from
peripheral conversion of plasma T4. Therefore, the T3
secreted by the thyroid gland constitutes only about 20 to
30% (1). These thyroid hormones are transported in the
circulation almost completely bound to specific proteins and
in a healthy adult only 0.03% of T4 and 0.3% of T3 circulate
in the unbound form. It is generally accepted that only the
free (unbound) hormones are physiologically active. The
major binding proteins in the circulation are thyroxine
binding globulin (TBG), thyroxine binding prealbumin (TBPA)
and albumin. Normally, about 70% of T4 and 75-80% of T3 is
bound to TBG, about 20% of T4 and 10% of T3 to TBP A and 10-
15% of each to albumin (2).
The secretion of thyroid hormones is under the control
of thyroid stimulating hormone (TSH) secreted by the
pituitary gland which is in turn controlled by the
thyrotropin releasing hormone (TRH) secreted by the
hypothalamus and the negative feedback of free hormones in
the circulation. The negative feedback is mediated by the
intracellular T3 which is converted from T4 taken up from
the circulation by the thyrotroph cells in the pituitary
gland. Under physiological circumstances, the pituitary
gland secretes more TSH when the circulating thyroid hormones
are low and conversely secretes less TSH when the circulating
thyroid hormones are high so as to maintain normal plasma
thyroid hormone concentrations (3). However, in
pathological conditions, there is over or under secretion of
thyorid hormones. These conditions are called
hyperthyroidism and hypothyroidism respectively. In most
cases, the signs and symptoms of hyperthyroidism and
hypothyroidism are very non-specific and the diagnosis
usually requires laboratory confirmation. Nowadays, there
are many thyroid tests designed for helping clinicians in
diagnosis or monitoring treatment of thyroid diseases.
However, while these tests have their usefulness in different
situations, they also have their limitations.
Total T4 (TT4)
Plasma total T4 concentration can now be measured easily
by radioimmunoassay (RIA)(4), fluorescence immunoassay
(FIAX5), enzyme immunoassay (EIA)6) or fluorescence
polarization immunoassay (FPIA)(7). Most of these tests can
be automated and a large number of samples can be assayed
quickly. Therefore, TT4 is commonly used by many
laboratories as the initial thyroid function test.
In the absence of abnormalities in thyroid hormone
binding, TT4 is a reliable indicator reflecting the thyroid
status and many overtly hyperthyroid cases can be confirmed
by a single TT4 test. However, thyroid hormone binding
abnormalities are not rare, and in these cases, TT4 cannot
accurately reflect the free hormone fraction or the
thyrometabolic status.
It is well known that oestrogen is a strong stimulator
for the production of TBG, and therefore, increased
concentration of TBG is a common finding in women during
pregnancy or in women taking oral contraceptive pills (8).
Abnormal TBG concentrations or binding affinities may also be
acquired genetically. X-linked TBG deficiency or excess are
well documented (9). TBG variants with reduced T4 binding
affinity are common findings in Australian aborigines (10).
Although TBG is the major thyroxine binding protein,
about 20 to 30% of the circulating thyroxine is bound to
albumin and prealbumin. Marked variations in albumin
concentration may be seen in cases of hereditary
anal buminemia or familial dysalbuminemic hyperthyroxinemia
(11). in the former case, there is no albumin present in
the circulation while in the latter case, albumin with
extremely high binding affinity is present in excess amount.
Thyroxine binding abnormalities may also be due to
commonly used drugs. Salicylate, diphenylhydrantoin and
fenclo fenac are known to displace thyroxine from the binding
proteins and thus decrease the T4 binding.
Free Thyroxine Index (FT!)
Free thyroxine index is derived from the values of TT4
and T3 Uptake. Since the protein binding capacity is taken
into account by the T3 uptake value, FTI is less influenced
by protein binding abnormalities. It is found that FTI is
more reliable in assessing thyrometabolic status than TT4
particularly when there is binding abnormality due to
oestrogen stimulated TBG excess (13). Despite the
introduction of free hormone assays in recent years, some
people still consider FTI to be the best thyroid function
test in diagnosis of thyroid disorders (14).
However, not all protein binding abnormalities can be
corrected by the T3 uptake test used to calculate the FTI.
Albumin does not bind T3 to the same extent as T4. Therefore,
binding abnormality due to albumin variation cannot be
accurately assessed by the T3 uptake test. In familial
dysalbuminemia hyperthyroxinemia, due to the increased
binding affinity of albumin to thyroxine but not to T3, T3
uptake test cannot correct this abnormal binding and the FTI
will be very high (11). FTI also fails to reflect free T4
concentration in TBG deficiency, where albumin and TBPA
become the major T4 binders (15).
Binding abnormal ities due to drug interference or non-
thyroid illness also cannot be accurately corrected by T3
uptake test (16).
Although direct measurement of TBG concentration is
available in recent years, the diagnostic value of TT4TBG
ratio is not better than FTI (17), because binding
abnormalities due to other proteins are not taken into
calcu1 ation.
Free T4 (FT4:
As FTI cannot completely correct for thyroxine binding
abnormalities, measuring the free hormones directly has
generally been considered as a desirable analytical goal.
However the research methods for measuring FT4 based on
equilibrium dialysis are too cumbersome for routine
diagnostic use (18). More convenient but less accurate
methods, such as immunoextraction (19) or analogue assays
(20) are more commonly used in clinical laboratory.
In the immunoextraction method, specific T4-antibody
attached to the inner wall °x a test tube is allowed to react with
free Tb in a diluted sample for a short period, the Tb that is bound
to endogenous proteins is then rinsed away. Subsequent
incubation with labelled T4 allows quantification of the
vacant antibody T4 binding sites, which are inversely
proportional to the sample FT4 concentration. This method
requires that during the first incubation step, the
equilibrium between free and bound hormones is not disturbed
and the antibody used only has the affinity to bind FT4 in
the sample but not to strip T4 that is bound to endogenous
binding protein. This method was found to correlate with
equilibrium dialysis method( r= 0.85) (21).
Another method commonly used in clinical laboratory is
the T4-ana1ogue immunoassay. In this method, the pertinent
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point is in the use of I-T4-analogue which presumably
competes with free T4 hormone for binding sites on antibody
but does not bind to endogenous proteins. However, the
analogues used in most commercial reagents do not behave
strictly to this theoretical requirement; they bind to
albumin and TBPA to various extent (22). Nevertheless, when
these commercial FT4 assays were used to discriminate simple
hyperthyroid patients from healthy euthyroid individuals,
sensitivities were reported to be 90-100% (23-24).
Comparing with the diagnostic performance of FTI, some
reports showed that FT4 has a better sensitivity (25), while
others found that FT 4, FTI and T4TBG are equal in
differentiating simple hyperthyroid patients from euthyroid
subj ects (24).
Usually, the analogues used in FT4 kits does not bind to
TBG, therefore, when there is binding abnormality due to
increased TBG, the analogues method can measure the free
fraction of T4 hormone accurately (26). However, the binding
of analogue to other endogenous proteins may lead to
overestimation of 'FT4' hormone. In euthyroid subjects with
familial dysalbuminemia hyperthyroxinemia, the abnormal
albumin does bind the T4 analogue in the assay, and gives a
falsely high result (27). On the other hand, undetectable FT
results may be obtained in euthyroid subjects with hereditary
ana 1buminemia (28).
Due to the undesirable binding of analogue to endogenous
proteins, reports on the clinical performance of FT4 assays
in different groups of patients were quite contradictory.
Many drugs, i.e. salicylate, dipheny1 hydrantoin or
fenclofenac, can displace T4 from the endogenous binding
proteins. The dialysis method gave slightly elevated FT4
results but results given by analogue methods were low
because the drug which displaces T4 from the endogenous
binding proteins also displaces T4-analogue from the
prote i ns(29). Therefore, in the RIA system, relatively more
T4-analogue will bind to T4-antibody, and the results
obtained will be low. Increased fatty acid concentrations
induced by intravenous administration of heparin or resulting
from non-thyro i da 1 illness also have similar displacement
effect and therefore FT4 results given by different methods
in these conditions are also very contradictory (30-31).
Occasionally, spuriously high FT4 values are obtained in
patients with T4 autoantibodies. These autoantibodies also
bind T4 analogue in the analogue T4 assay system. Binding of
the analogue to autoantibodies thus allow more T4 to react
with the exogenous T4 antibody and thus falsely elevated T4
results are obtained (32)
TOTAL T3( TT3) and FREE T3( FT3)
Most assay techniques available for TT4 and FT4 are also
available for measuring TT3 and FT3. Since approximately
99.7% of plasma T3 is bound to the same transport proteins as
T4, the diagnostic value of TT3 is also diminished by binding
protein abnormalities.
Determination of TT3 or FT3 is most useful in the
diagnosis of 'T3-toxicos i s' which by defination cannot be
identified by T4 assays. It has been suggested that FT3
might provide a more accurate discriminator of hyperthyroid
state than any other single thyroid hormone assay (33),
however, available data fail to show a clear advantage of FT3
over FT4 (34).
In the diagnosis of hypothyroidism, T3 is found to be the
least sensitive indicator. Even in advanced hypothyroidism,
normal T3 concentrations are usually still maintained (35).
In patients with nonthyroidal illness, decreased T3
concentration is the most common non-specific finding and
determination of T3 is not helpful in differentiation of
hypothyroidism from sick euthyroid syndrome (36).
In hypothyroid patients who are receiving thyroxine
replacement therapy, perhaps an elevated FT3 result is the
best indicator for hormone over-replacement. In this group
of patients the monode i od i nat i on of circualting T4 is the
only source of T 3, and a relatively higher plasma T 4
concentration is required for normal physiological function,
therefore an elevated TT4 or FT4 do not necessarily imply
over treatment (37).
Thyroid stimulatina hormone (TSH)
Radioimmunoassay for TSH was developed more than 20
years ago and has been successfully used for the confirmation
of hypothyroidism, for assessing the pituitary response to
TRH stimulation and for assessing the thyroid hormone
replacement therapy.
However, the application of this test in the diagnosis
of hyperthyroidism has been unsuccessful because conventional
RIA methods for TSH measurement are not sensitive enough to
differentiate suppressed TSH concentrations in
hyperthyroidism from normal euthyroid concentrations.
In case of borderline hyperthyroidism, diagnosis has to
depends on the TRH stimulation test. In a normal subject, at
least a 2 fold increase of TSH will be found 20 minutes after
intravenous administration of 200 ug of TRH. Hyperthyroid
patients shows no or blunted response to TRH stimulation.
However, the test causes unpleasant side effects in up to 50%
of subjects and is not without serious risk in occasional
cases (38).
In recent years, reagent kits using immunometric
techniques and monoclonal antibodies have become widely
available commercially. These assay kits, on the whole, have
much improved sensitivity over the conventional RIA kits.
Initial studies on these sensitive kits have shown that they
are able to help in the detection of hyperthyroidism (39-40).
Most kits are sensitive enough to differentiate hyperthyoid
TSH concentrations from euthyroid TSH concentrations although
the analytical and clinical performance of these kits many
vary substantially (41).
As suppression of the pituitary gland in hyperthyroidism
can be readily demonstrated by sensitive TSH assays, it was
suggested that TRH stimulation test could be abandoned (42).
Seth et al showed that in a study of 110 overt hyperthyroid
patients, all patients had suppressed basal TSH
concentrations and did not respond to TRH stimualtion (43).
However, in another study, a significant number of patients
showed detectable response to TRH despite their suppressed
TRH concentrations. They commented that abandonment of TRH
test will prevent the identification of patients who are
still capable of subnormal response to TRH (44).
Since it has become possible to detect hyperthyroidism
as well as hypothyroidism by sensitive TSH assays, many
people suggested that it would be more effective if TSH is
used as a first line screening test (45-46). However, apart
from economic and technical reasons, the limitations of
sensitive TSH assays have to be considered. Although the
sensitivity of most sensitive kits for detecting
hyperthyroidism is nearly 100%, suppressed TSH concentrations
are frequently encountered in the following conditions.
a. Thyroxine replacement therapy
Suppressed TSH is a common finding in patients receiving
thyroxine replacement. The suppressed TSH concentration
is probably the result of high plasma T4 concentration which
is required to provide sufficient T3 for normal physiological
function since deiodination of T4 is the onlv source of
T3 in hypothyroid patients. Therefore, a suppressed TSH
concentration in these patients does not indicate over-
replacement. However, an elevated TSH concentration does
indicate that thyroxine replacement is inadequate (47).
thyroxine replacement is inadequate (47).
b. Treated hyperthyroidism
A large percentage of hyperthyroid patients have low
TSH concentration even after successful treatment because the
suppressed pituitary glands in hyperthyroid patients take
several weeks to recover its responsiveness (48-49).
c. Drugs
Drugs that oppose TRH action, including glucocorticoids,
dopamine, L-dopa, bromocriptine, etc., can reduce TSH
secre tion (50).
d. Nonthyroidal illness
In non-thyroida 1 illness, TSH may be reduced due t
increased secretion of Cortisol and dopamine which compete
with TRH and inhibit the secretion of TSH. In one study.
it was found that 17 of 35 marrow transplant patients had
suppressed TSH concentrations (51).
The present study
Since sensitive TSH assay is still relatively new to
some laboratories and reports in the literature reveal that
different kits may have different performances (41,51). The
current study is to evalute the analytical and clinical
performance of six sensitive TSH kits, of which five were use
the immunoradiometric technique and one uses the
immunochemiluminometric technique.
In the analytical part, the lowest detection limits,
precision profiles, correlation and regression of results
from different kits were studied.
In the clincal part, six sensitive TSH assays, TT4, T3
uptake, FT4, TT3 and FT3 were performed on samples collected
from different groups of people including 71 healthy
euthyroid subjects, 35 untreated hyperthyroid patients, 31
successfully treated hyperthyroid patients and 78 pregnant
women. In the hyperthyroid patients, the diagnostic
sensitivity of the six TSH assays and other thyroid function
tests were compared. In the treated hyperthyroid cases, the
clinical usefulness of sensitive TSH assays in monitoring
treatment was investigated. TSH and other thyroid hormones
during first, second and third trimester were also measured
and compared to non-pregnant values. Finally, a thyroid
function testing strategy including sensitive TSH assays is
suggested.
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3. 1 Mater ials
3.1.1 Blood samples
5 ml blood samples were collected from the following
subjects between 9:00 am to 12:00 noon in heparinized
bottles. The plasma was separated and stored below-
20°C until analysis.
3.1.1.1 Normal subjects
Blood samples were collected from 12 males and 59
females( ages 19 to 81 years, 18% above 60). None of
these persons had history of thyroid disorders.
3.1.1.2 Hyperthyroid patients
This group included 23 untreated thyrotoxic patients
and 12 previously treated hyperthyroid patients who
developed thyrotoxic symptoms after stopping
treatment for at least 3 months.
The patients ages were 16-63 years and 33 of them
we re fe ma 1e.
3.1.1.3 Thyrotoxic patients recovered after treatment
Samples were taken from 31 thyrotoxic patients who
had recovered and showed no signs of thyrotoxicosis
at the time of sampling.
3.1.1.4 Pregnant women
Samples were collected from 78 pregnant womer
attending antenatal clinic for routine check-up.
There were equal number of samples were from first,
second and third trimester of pregnancy.
3-1.1,5 Control sera
Ligand A,B,C control sera (Lot no. LIG 602) given b
Ciba-Corning Diagnostic Corporation were used for
assessing the precisions of TSH kits. Lyhocheck
controls were used for T3 uptake, FT4, FT3 and TT3.
Abbott TDX T4 controls were used for TT4.
3.2 Methods
Six sensitive TSH assays, total T4, T3 uptake, free
T4, total T3 and free T3 assays were carried out on
the samples and control sera using the methods
be 1ow:
3.2.1 Abbott RIABEAD II TSH assay
3.2.1.1 Reage nts:
a. mouse monoclonal anti-TSH coated beads
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b. I mouse monclonal anti-TSH antibody
c. TSH standards: 0, 0.1, 0.6, 4.0, 30 and 200
mlUL.
3.2.1.2 Equipment and assessories
a. Gamma counter
b. Quickwasher, rotator, reaction trays, cover
seals and counting tubes
3.2.1.3 Procedures
a The anti-TSH coated beads were carefully loaded
to the wells of the reaction trays followed by 200 ul
of samples, standards and controls.
b. The reaction trays were placed on the platform of
a rotator at 200 RPM and incubated at room
temperature for 2 hours.
c. The reaction trays were placed onto the
Quickwasher supplied by Abbott and the beads were
washed automatically.
d. 200 ul of labelled anti-TSH antibody reagent was
added to each well and steps b and c repeated.
e. The beads were transferred to 12x75 mm plastic
tubes and the radioactivity measured in a gamma
counter.
f. Results were read off from the calibration
curve.
3.2.2 Amersham Amerwell TSH assay
3.2.2.1 Reagents
a. microtitre plates with mouse monoclonal anti-TSH
coated we 11s.
b.I labelled mouse monclonal anti-TSH antibody
reagen t.
c. TSH standards: 0, 0.2, 1.0, 2.4, 5.0, 14.8, 52 and
194 mIUL.





a. 50 ul of labelled anti-TSH antibody was added to
each well of the microtitre plate followed by 200 ul
of sample, standard or control.
b. The microtitre plate was incubated at room
temperature on an Amerwell shaker for 2 hours.
c. The wells were washed 4 times with distilled water
using an Amerwell microtitre plate washer.
d. The wells were detached from each other and
placed into 12x75 mm plastic tubes for measuring the
radioactivity.
e. Results were read off from the calibration curve
3.2.3 Corning Magic mab TSH IRMA
3.2.3.1 Reagents:
a. sheep anti-human TSH antibody bound to
paramagnetic particles suspended in phosphate buffer.
b. 125I-labelled mouse monoclonal antibody reagent.
c. TSH standards: 0, 0.27, 1.0, 4.0, 20, 40 and 100
mlUL.
3.2.3.2 Equipment and assessories
a. Gamma counter
b. Multi-tube Vortex
c. Magnetic separator unit
3.2.3.3 Procedures:
a. 200 ul of sample, standard or control serum was
pipetted into 12x75 mm plastic tubes followed by 100
ul of labelled antibody reagent. The tubes were
mixed 3 times on a vortex mixer for 5 seconds and
incubated at room temperature for 2 hours,
b. 750 ul of well mixed anti-TSH bound paramagnetic
particles was added to each tube, mixed and
incubated for 30 minutes as above.
c. The tubes were placed on the lower part of a
magnetic separator for five minutes. The liquid phase
was then decanted by inverting the magnetic separator
and drained for a few minutes.
d. The rack holding the tubes was separated from the
magnetic separator and 1 ml of distilled water was
added to each tube followed by gentle mixing.
e. Steps c ,d and c were repeated. The tubes were
then put in a gamma counter for measuring the
radioacitvity.
f. Results were read off from the calibration curve.
3.2.4 Hybritech Tandem-R TSH assay
3.2.4.1 Reagents:
a. Mouse monoclonal anti-TSH coated beads.
b. 125I- labelled mouse monclonal anti-TSH antibody
reagent
c. TSH standards: 0, 0.25, 0.5, 5, 15, 30 and 60
mlUL.





a. The anti-TSH coated beads were removed from the
container, blotted on a paper towel and loaded
carefully into test tubes.
b. 100 ul of labelled anti-TSH antibody reagent and
200 ul of sample, standard or control were added to
each tube.
c. The tubes were mixed by shaking and incubated at
room temperature on a horizontal rotator at 170 RPM
for 2 hours.
d. The beads were washed three times with the
Hybriwash and the radioactivity measured in a gamma
counter.
e. Results were read off from the calibration curve.
3.2.5 Boots Celltech Sucrosep TSH assay
3.2.5.1 Reage nts:
a. Monoclonal anti-TSH antibody attached to solid
phase.
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b. I-1abelied monoclonal anti-TSH antibody reagent.
c. Sucrose solution.
d. Prewash buffer.
e. TSH standards: 0, 0.09, 0.31, 0.81, 4.0, 15.8,
64.2 mlUL.
3.2.5.2 Equipment and assessories
a. Gamma counter
b. Orbital agitator
c. Vortex, sucropette, sucroaspitator
3.2.5.3 Procedures:
a. 100 ul of labelled TSH antibody reagent and 100 ul
of sample, standard or control were added into 12x75
mm plastic tubes. Mixed well and incubated at room
temperature for 2 hours.
b. The solid phase antibody reagent was mixed well
and 100 ul was pipetted into each tube.
c. The tubes were placed on an orbital agitator at
300 RPM and incubated for 1 hour at room temperature.
d. 1 ml of prewash buffer was added to each tube and
allowed to stand for 5 minutes.
e. A set of sucropettes were carefully inserted into
the test tubes. 2 ml of sucrose solution was
dispensed to each tube slowly through the
sucropettes, after which the sucropettes were
re mo ved.
f. The solid phase was allowed to settle for 15
minutes, then the supernatant was removed by a
sucroaspirator.
g. Steps d,e and f were repeated.
10. The radioactivity in the tubes was measured in a
gamma counter.
11. Results were read off from the calibration curve.
3.2.6 Corning Magic Lite TSH ICMA
3.2.6. 1 Reagents:
a. Mouse monoclonal anti-TSH antibody bound to
paramagnetic particles.
b. Acridinium ester-labelled mouse monoclonal anti-
human TSH antibody reagent.
c. Calibrators: 0 and 15.7 mlUL.
3.2.6.2 Equipment and assessories
a. Magic Lite chemi-1 urninometer
b. Vortex Mixer
c. Magnetic separator unit
3.2.6.3 Procedures:
a. 100 ul of sample, standard or control was pipetted
into 12x75 mm plastic tubes followed by 100 ul of
acridinium ester-labelled anti-TSH antibody reagent.
The tubes were mixed 3 times for 5 seconds on a
vortex mixer and then incubated at room temperature
for 2 hours.
b. 500 ul of well mixed anti-TSH bound paramagnetic
particles was added to each tube. The tubes were
mixed and incubated as above for 30 minutes.
c. The rack holding the tubes was aligned on a
magnetic separator for five minutes and the liquid
phase decanted by inverting the magnetic separator
and drained for a few minutes.
d. The rack was separated from the magnetic separator
and 1 ml of distilled water was added to each tube
followed by gentle mixing.
e. Step c was repeated.
f. 100 ul of distilled water was added to each tube.
g. The luminescence in the tubes was measured with a
luminometer provided by the manufacturer of the
reagent kit.
h. A calibration curve was programmed in the
instrument for calculating the results.
3.2.7 TDX total T4 assay
3.2.7.1 Reagent s:
a. T4 plus reagent kits containing pretreatment
buffer, sheep anti-T4 antibody and fluorsecein
labelled T4 tracer.
b. T4 calibrators: 0, 38, 77, 154, 231, 309 nmolL.
3.2.7.2 Equipment and assessories
a. TDX system
b. Sample cartridges and cuvettes
3.2.7.3 Procedures:
Approximately 100 ul of samples were pipetted to the
sample well in the cartridges and loaded into the
carousel. The TDX system performed the test
au tomatical1y.
3.2.8 Coat-A-Count T3 uptake CDPC)
3.2.8.1 Reagents:
a. Anti-T3 antibody coated tubes.
b. 125I-labelled T3 reagent.
3.2.8.2 Procedures:
a. 25 ul of sample or control and 1.0 ml of labelled
T3 reagent were added into the anti-T3 antibody
coated tubes. A tube without adding sample was set up
for total binding.
b. The tubes were mixed and incubated at room
temperature for 1 hour.
c. The supernatant was removed by aspiration and the
radioactivity in the tubes was measured in a gamma
counter.
d. The T3 uptake was calculated as follows:
count of sample tube
T3 uptake
count of total binding
3.2.9 Gamma Coat Free T4 assay (Clinical Assays)
3.2.9.1 Reagents:
a. labelled T4 reagent.
b. Rabbit anti-T4 antibody coated tubes.
c. T4 standards: 0, 2.2, 9.3, 20.6, 33.5 and 70.8
pmo1L.
3.2.9.2 Procedures:
a. 50 ul of sample, standard or control and 1.0 ml of
incubation buffer were pipetted into the anti-T4
coated tubes.
b. The tubes were mixed well and incubated at 37 C
for 20 minutes.
c. The supernatant was removed by aspiration.
d. The tubes were washed by adding 1 ml of incubation
buffer and removed by aspiration.
e. 1.0 ml of labelled T4 reagent was added to the
tubes.
f. The tubes were incubated at room temperature for 1
hour.
g. The supernatant was removed by aspiration.
h. The tubes were placed in a gamma counter for
measuring the radioactivity.
i. Results were calculated from the calibration curve
automatical1y.
3.2.10 Coat-A-Count Total T3 assay (DPC)
3.2.10.1 Reagents:
a. T3 antibody coated tubes.
1 25
b. Buffered I labelled T3 reagent.
c. T3 calibrators: 0, 0.31, 0.77, 1.54, 3.07 and
9.22 nmo1L.
3.2.10.2 Procedures:
a. 100 ul of sample, calibrator or control was added
into the T3 antibody coated tubes and followed by
1.0 ml labelled T3 reagent.
b. The tubes were mixed well and incubated at
37 C for 2 hours.
c. The supernatant was removed by aspiration and the
tubes were put in a gamma counter for measuring the
radioactivity.
d. Results were read off from the calibration curve
au tomatica11y.
3.2.11 Coat-A-Count Free T3 assay (DPC)
3.2.11.1 Reagents:
a. T3 antibody coated tubes.
1 25
k I labelled T3 analogue reagent.
c. Free T3 calibrators: 0, 0.69, 2.00, 4.61, 9.22.
32.26 and 67.58 pmolL.
3.2.11.2 Procedures:
a. 100 ul of sample, calibrator or control was added
to the T3 antibody coated tubes and followed by 1.0
ml labelled T3 analogue reagent.
b. The tubes were mixed and incubated at 37 C for 3
hours.
c. The supernatant was removed by aspiration and the
tubes were put in a gamma counter for measuring the
radioactivit y.
d. The results were read off form the standard curve
automatical1y.
3.2.12 Free Thyroxine Index (FTI)
The FTI was calculated as:
(Total T4 concentration) x T3 uptake
mean value of T3 uptake in healthy subjects
3.3 Stat i s tics
The coefficients of variation (CVs), coefficients of
correlation (r), slopes and intercepts of regression
lines of results obtained from different TSH kits
were calculated by computer using the Abstat
statistics program.
Mean values of results from different groups
were compared by using the Student's t test.
Coefficient of skewness and kurtosis were
calculated as below (52):
coefficient of skewness:
coefficient of kurtosis:
where E is the expected value
x is the random variable
j is the sample mean




Table 1 lists the detection limits of the six sensitive
TSH kits. The detection limit is defined as the lowest
concentration of TSH that can be statistically differentiatec
from the zero calibrator. In this study, the zero calibrator
was processed as unknown sample in 20 replicates, from whict
the mean value and standard deivation (SD) of the counts were
calculated. The TSH concentration corresponding to the mear
plus 2 SD of the counts was read off from the' calibration
curve and taken as the detection limit. In the Corning ICMA
kit since the calibration curve was not available, the
detection limit was calculated by dividing the value of 2 SC
count by the slope of the calibration curve.
The lowest detection limit of 0.02 mlUL was given by
Corning ICMA kit. The slope of the calibration curve was
also the highest in this kit. The detection limit of Abbott
kit was 0.03 mlUL, slightly higher than that of Corning ICMA
kit. The detection limit of the Boots kit was 0.18 mlUL much
higher than the 0.08 mlUL claimed by the manufacturer.
4.1.2 Precision
The precision profiles performed on the Corning Triligand
A.B C Control are shown in Table 2.
n the intra-assay precision profiles, the
coefficients of variation (CVs) of different kits at medium
and high TSH concentrations were less than 10%. At TSH
concentration of about 1.0 mlUL, the CVs of Hybritech kit
and Boots kit were slightly over 10%.
The inter-assay precision of Boots kit was least
satisfactory, with CVs over 28% for the low control. (Table
3).
The Abbott kit showed consistently low CVs in the
intra-assay and inter-assay runs.
Precision profiles of TT4, T3 uptake, FT4, TT3 and FT3
are shown in Table 4.
4.1.3 Accuracy
Marked differences in mean values were obtained from
different kits when aliquots of the same control serum were
analysed. The differences were particularly obvious at high
concentrations. In the intra-assay precision run, the mean
value of high control obtained by Hybritech was 36.10 mlUL
but that obtained by Boots kit was only 12.03 mlUL, about
13 of the Hybritech value. At medium concentration, the
value obtained by Boots kit was also about 13 of the value
obtained by the Hybritech kit. Taking the Abbott kit results
as independent variables, the coefficient of regression on
other kits ranged from 0.5 to 1.40(Amerwe11= 0.86 Abbott+
0.25, Corning IRMA= 0.89 Abbott+ 0.39, Hybritech= 1.40
Abbott+ 0.10, Boots= 0.50 Abbott+ 0.92, Corning ICMA
=0.66 Abbott +0.15)
Table 2- Intra-assay precision profiles of the six
sens i tive TSH kits









mean (mlUL) 0.75 7.34 24.20
SD 0.04 0.32 0.42
CV% 5.2 2.5 1.7
mean (mlUL) 0.98 6.94 21.58
SD 0.07 0.23 0.42
CV% 7.2 2.4 1.9
mean (mlUL) 1.17 8.76 23.31
SD 0.09 0.43 0.73
CV% 7.6 2.6 3.1
mean (mlUL) 1 ,04 1 1 .-1 1 36, 10
SD 0,11 0.73 2.61
CV% 10.6 5.4 7.2
mean (mlUL) 1.30 4.73 12.03
SD 0.16 0.58 0.72
CV% 11.9 8.7 6.0
mean mIUL 0.88. 6.37 17.21
SD 0,07 0.4 f 0.65
CV% 6.3 4.6 3.8
CIba-Corn1ng Trlllgand control n- 20)
TABLE 3- Inter-assay precision profiles of the six
sensitive TSH kits









Abbo11 kit mean (mlUL) 0.84 7.36 26.68
SD 0.06 0.18 1.16
CV% 7.4 4.4 4.4
Amerwe11 kit mean (mlUL) 0.93 6.72 22.37
SD 0.08 0.16 0.78
CV% 8.8 3.5 3.5
Corning IRMA mean (mlUL) 1.12 8.91 23.13
SD 0.10 0.23 1.63
CV% 8.9 4.8. 7.0
Hybritech mean (mlUL) 0.98 10.35 32.59
SD 0.10 0.60 3.38
CV% 10.8 7.1 10.3
Boots Sucrosep mean (mlUL) 1.03 3.55 10.79
SD 0.29 0.41 0.96
CV% 28.5 16.5 9.0
Corning ICMA mean (mlUL) 0.74 5.87 15.96
SD 0.06 0.33 1.04
CV% 7.8 6.6 6.5
Ciba-Corning Triligand control (n- 5 x 4)








TT4 mean+ SD 54± 3.6 91+ 4.5 187+ 6.8
CV% 6.7 5.0 3.6
T3 uptake mean+ SD 28.2+ 1.1 32.7+ 1.0 39.1+ 1.5
CV% 4.0 3.1 3.7
FT4 mean+ SD 5.9+ 0.5 18.5+ 1.3 58.3+ 5.8
CV% 7.6 7.0 10.6
TT3 mean+ SD 1.2+ 0.15 3.1+ 0.22 6.97+ 0.33
CV% 13.1 7.1 4.8
FT3 mean+ SD 1.8+ 0.24 6.3+ 0.48 12.0± 1.3
CV% 13.6 7.6 10.6
N= 2 x 5
Control sera for TT4: Abbott TDX T4 control
Control sera for T3 uptake, TT3, FT4, FT3: Lyhocheck
control
On correlation analysis, results of the control sera obtainec
from different kits were excellent( r= 0.97- 0.99).
However, regression and correlation analysis on the
150 sample results above detection limits determined by
different kits showed that the regression coefficients are
closer to 1 and the constant bias are nearer to zero. Again
taking the Abbott kit result as independent variable, the
regression coeffients ranged from 0.95 to 1.54( Amerwell=
1.09 Abbott- 0.12, Corning IRMA= 1.28 Abbott -0.29,
Hyritech= 0.95 Abbott- 0.3, Boots= 0.85 Abbott- 0.30,
Corning ICMA= 1.00 Abbott -0.05). On correlation analysis,
except the Boots kit and Amerwell kit all the coefficients of
correlations are above 9.0 (Table 5).
TABLE 5- Correlation matrix of sensitive TSH kits






Abbott Amerwell Corning Hybrit. Boots
0. 86
0.95 0.82
n qr n 8i 0.89
0.85 0.82 0.83 0.84
0.94 0.85 0.91 0.90 0.83
4.2 CLINICAL PERFORMANC;
4.2.1 Healthy subjects
The distribution of TSH concentrations in healthy
euthyroid subjects was skewed (skewness= 2.0-2.3, kurtosis=
3.8-5.2) and therefore log transformation was required to
establish the reference range. The distributions of TSH
concentrations obtained by different assays are shown in
Figures 1 to 6 in log scale. The mean values and reference
ranges of TSH obtained from the 71 healthy euthyroid subjects
were listed out in Table 7. The lower limits were about 0.3
to 0.4 mlUL and the upper limits were about 3 to 4 mlUL.
No significant differences were found in the results obtained
from 12 male subjects and 59 female subjects, or results
from 12 subjects over 60 years of age and those below.
However, it was found that in the 71 healthy subjects, 2
female subjects had low TSH values clearly distinguishable
from the other healthy subjects. These two subjects were
clinically euthyroid and they had other thyroid function test
results within the reference range (Table 6).
Table 6- Thyroid function test results of the two




TT4 FTI FT4 TT3 FT3
nmolL nmolL pmolL nmolL pmolL
141 140 19.5 1.7 4.0
118 118 14.7 1.3 2.2
4.2.2 Pregnant women
The TSH values obtained from the 78 pregnant women
in first, second and third trimester are also shown shown in
figures 1 to 6. The mean values and reference ranges are
also shown in Table 7.
It can be seen that the TSH values of women in the
first trimester of pregnancy obtained by different kits were
significantly lower (Unpaired Student's t test, p0.01) than
those found in healthy non-pregnant subjects. In the second
and third trimester of pregnancy, although slightly lower TSH
values stilled existed but they were not statistically
significant (p 0.1).
TT4, FTI, FT4, TT3, FT3 and T3 uptake also showed
significant changes during pregnancy. TT4, TT3 and FT3
increased by 53%, 67% and 59% respectively in the second
trimester of pregnancy. FTI also increased in pregnancy but
the peak was in the first trimester and the mean value was
only 21% above the reference mean. T3 uptake and FT4
decreased progressively during pregnancy. These changes are
shown in figure 12.
4.2.3 Hyperthyroid patients
Determined by the six sensitive TSH kits, the TSH
concentrations of the 35 hyperthyroid patients were all below
the lower reference limits. The distribution of TSH values
obtained in this group of patients can be found in figures 1
to k. Results of other thyroid function tests on these
patients can be found in figure 7 to 11. From these figures,
the diagnostic sensitivities of TT4, FTI, FT4, TT3, FT3 and
TSH were calculated and are listed in Table 8. While the
sensitivity of TSH in the diagnosis of hyperthyroidism was
found to be 100%, the sensitivities of other thyroid tests
ranged from 94% to 97%.
Table 9 shows the degree of change of TT4, FTI, FT4,
TT3 and FT3 in patients with hyperthyroidism. In this group
of patients, the mean values of TT3 and FT3 were
approximately 3 times above the reference mean. FT4 was 2
times above reference mean. However, if the degree of
elevation is expressed in terms of standard deviation of
reference values, FT4 was 14.5 SD above the reference mean
while TT3 and FT3 were only elevated by 11.1 SD and 10.7 SD
re spective1y.
4.2.4 Treated hyperthyroid patients
Results obtained from different sensitive TSH kits
showed that at least 20% of this group of patients had TSH
values below reference values. Table 10 showed the number of
patients who were found to have suppressed TSH values when
the results were obtained by different kits.
The distributions of TSH values of these patients
determined by different kits can be found in Figures 1 to 6.
The distributions of TT4, FTI, FT4, TT3 and FT3 are
shown in Figures 7 to 11.
Table 11 shows the number of patients who had thyroid
hormone results above upper reference limits. It was found
that about 30% of these patients had TT3 and 12% had FT3
above the upper reference limits.
However, these elevated T3 values did not correlate with
the suppressed TSH values (r- 0.25).
TABLE 7- TSH and thyroid functi on tests values in





TT4 mean nmolL 105 145 160 139
range 61-149 78-212 110-210 89-189
FTI mean nmolL 104 126 122 101
range 61-148 78-174 76-168 70-132
FT4 mean pmolL 15.8 13.7 11.6 9.5
range 10.8-20.8 8.6-18.8 6.6-16.6 5.3-13.7
TT3 mean nmolL 1.4 2.2 2.4 2.1
range 0.7-2.1 1.1-3.3 1.6-3.2 1.2-3.0
FT3 mean pmolL 2.7 3.9 4.5 3.4
range 1.0-4.4 2.2-5.6 2.9-6.1 1.1-5.7
T3U mean% 30.2 28.2 24.7 23.5
range 22.6-37.8 23.2-33.2 20.1-29.3 18.5-28.5
TSH (Abbott)
mean (mlUL) 1.13 0.70 0.97 1.15
range 0.3—3.0 0—1.6 0.1—1.8 04-2.7
TSH (Amerwe11)
mean (mlUL) 1.27 0.78 1.02 1.12
range 0.4—3.5 0.1—1.7 0.3—1.9 0.5—2.5
TSH (Corning IRMA)
mean (mlUL) 1.24 0.73 1.23 1.4
range 0.4-3.2 0-1.8 0.2-1.9 0.4-2.
TSH (Hybritech)myUI l uc: Oil
mean (mlUL) 0.95 0.61 0.83 0.85
= 0.3-2.8 0-1.5 0.2-1.8 0.4-2.4
TSH (Boots)DUUlo
mean mIUL) 1.75 1.00 1.31 1.65
o 4-4 9 0-2.4 0.2-2.5 0.8-4.6
TSH (Corning ICMAi(Corning ilma;
mean (mlUL) 1.11 °-66 ;0' 4or
range 0.3-3.2 0-1.8 0.1-2.3 0.4 2.8
TABLE 8- Sensitivity of thyroid function tests in the
diagnosis of hyperthyroidism
Te s t
no. of results within


































TABLE 9- Degree of elevation in the mean Vcilues of
thyroid function tests in the hyperthyroid





















TABLE 10- Treated hyperthyroid patients with TSH values
below lower reference limits



















TABLE 11- Treated hyperthyroid patients with thyroid
function above upper reference limits
















figure 1- TSH concentrations in euthyroid subjects,
treated and untreated hyperthyroid patients
and pregnant women- determined by Abbott



























Figure?.- TSH concentrations in euthyroid subjects
treated and untreated hyperthymic! patients
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Figure 3- TSH concentrations in euthyroid subjects,
treated and untreated hyperthyroid patient














Figure k- TSH concentrations in euthyroid subjects
treated and untreated hyperthyroid patients




























Figure 5- TGH concentrntions in euthyroid subjects,
treated and untreated hvperthyroid patients
and pregnant women- determined by Boots


























Figure 6- TSH concentrations in euthyroid subject:
treated and untreated hyperthvroid pntienl
and pregnant women- determined by Oorninf


























Figure 7- TT+ concentrations in euthyroid sub.jecl
• treated and untreated hynerthyroid patier



























Figure 9- FTH concentrations in euthyroid subjects,
treated and untreated hyperthyroid patients





























Figure 10- TT; cuncentrat inns in euthyroid sub jects.,
treated and untreated hyperthyroid patients





























Figure 11- FT5 concentrations in euthyroid. subjects,
treated and untreated hyperthyroid patients






















Figure 12- Changes of TSH nnd thyroid hormones concentration
during 1st, 2nd and 3rd trimester pregnancy
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In this study, the detection limit of the TSH assays is
defined as the lowest concentration of TSH that can be
statistically differentiated from the zero calibrator.
Although this definition is widely used for comparision of
sensitivity, it has been criticized for lack of clinical
significance because usually the coefficient of variation at
this limit is over 10% and the analyte cannot be precisely
measured. It is suggested that detection limit should be
defined as the lowest concentration of an analyte that can
be precisely measured (CV not greater than 10% or 15%) (53).
This requires that a precision profile curve around the
detection limit be constructed, from which the concentration
corresponding to 10% CV is read off and taken as the
workable detection limit. In this study, this workable
detection limit is not used because:
a. There was no control material with TSH concentration low
enough for constructing the precision profile curve around
the detection limit and dilution of the control sera or
standards were necessary. However, only the zero calibrator
supplied by individual kits was recommended for dilution
purpose. Ihe supply of zero calibrator in each kit was very
limited and zero calibrators from different kits were not
interchangeable. The zero calibrator supplied by Hybritech
kit read 0.2 mlUL when assayed by the Amerwell kit.
b. Even if the precision profile curve can be constructed and
the workable detection limit of the individual kit measured,
it is dificult to compare the results because a large
discrepancy was observed when the same aliquot of control
serum was assayed by different kits. Therefore, the control
serum may be found to have 10% CV in different kits but those
kits giving low results will appear to have lower detection
1 i m i t s.
Although the definition of detection limit used in this
study does not mean that TSH can be precisely measured at
such concentration, it is good enough for comparision of the
sensitivities of different kits. Basically, the detection
limit depends on two factors. One is the fluctuation of the
counts of the zero calibrator and another is the slope of the
calibration curve. The smaller the fluctuation of counts
and the greater the slope, the lower is the detection limit.
In the Boots kit, the slope is small. In the Corning IRMA
kit, the fluctuation of the counts of zero calibrator is
large. Therefore, these two kits had high detection limits.
Although an immunochem i 1um i nometric assay (ICMA) has
been reported to be 10 to 20 times more sensitive than
immunoradiometric assays (IRMA)(54), this study found that
the detection limit of the Corning ICMA kit (0.02 mlUL) was
only slightly lower than that of the Abbott IRMA kit (0.03
mlUL). Although the slope of the calibration curve in the
Corning ICMA kit was about 20 times that of other IRMA kits,
the SD of the counts of zero calibrator was 14 times that of
the Abbott kit, therefore, the detection limit showed not
much difference.
5.1.2 Precision
On the whole, the precision of the six sensitive TSh
kits were acceptable except the Boots kit which hac
unsatisfactory CVs at low TSH concentrations. The poor
performance of Boots kit was probably due to the complicated
procedures and low counts in the assay tubes. In the Corning
ICMA kit, unstable background luminescence probably
diminished its precision.
5.1.4 Accuracy
Discrepancies of results were found to be highest in the
Boots and Hybritech kits when the Ciba Corning Triligand
control sera were assayed. However, the results on the
control sera at low, medium and high concentrations were
parallel to each others. However, less discrepancies were
found in the results of the samples. This indicates that
certain kits were influenced by substances present in the
control sera or because the matrix of the control oera w a
different from the samples.
5. 1. 4 P r a c t i c a b i 1 11 y
The major difference in the six sensitive kits in this
study is the solid phase used to attach the TSH antibodies.
The Abbott kit and Hybritech kit used macrobeads about 4 mm
in diameter; the Amerwell kit used the wells of micro-titre
plates; the other kits used fine particles. Although
theoretically antibody attached to macro-surface is
kinetically unfavouable because the surface area is limited,
this study showed that the analytical performance of kits
using macro-surface and micro-particles were not much
different. In practice, kits using macro-surface are easier
to handle particularly in the washing step. Therefore, for




The reference ranges obtained from the healthy subjects
are similar to those obtained from other report (55). The
lower reference limit of 0.3 to 0.4 mlULi and the upper
reference limit of 3 to 4 mlUL are much lower than the
reference limits established by conventional RIA methods (1-
lOmlUL). This is probably due to the better sensitivity and
precision of immunometric assays.
5.2.2 Pregnant women
The well established pattern of elevated serum total
thyroid hormones and decreased T3 uptake values was also
observed in this study. These changes were not associated
with an increase in serum F T 4, which in fact progressively
decreases throughout the pregnancy. These results are in
good agreement with reports from some authors (56-57). On
the other hand, unchanged (58), and elevated (59) FT4 values
were reported by others in different periods of pregnancy.
These discrepancies might be due to differences in methods
employed. Similar to the changes in FT4, FT3 has also been
reported to be increased (60), not changed (61) or decreased
(62). In this study, FT3 was found to increase steadily
during pregnancy until the second trimester, after which it
returns towards non-pregnant values.
Reports on TSH values during pregnancy based on
sensitive assays are relatively rare in the literature.
Early studies using RIA techniques found low TSH values in
pregnancy (63-64). During the first trimester pregnancy,
blunted TRH response were also reported (64). This study
found that TSH was significantly lower during the first
trimester of pregnancy. At least 15% of the pregnant women
in the first trimester had undetectable TSH results.
However, one study using the Boots kit showed that TSH
increased progressively during pregnancy (65). The author
suggested that the discrepancies might be due to the low
sensitivity and cross-reaction with HCG in the RIA TSH assays
in previous studies. However, cross-reaction with HCG would
only have given elevated TSH values in RI,
As the molecular structure of TSH is very similar to HCG
and TSH is suppressed to the greatest extent during the first
trimester of pregnancy, it is suggested that large amount of
HCG present in the circulation might be able to stimulate the
thyroid gland and the suppressed TSH concentration is a
normal response to this physiological change.
5.2.3 Hyperthyroid patients
Although it has been reported that some hyperthyoid
patients had TSH values overlapping the normal reference
range (41) when the Boots kit was used, this study found that
all hyperthyroid patients had TSH values, measured by all the
six sensitive TSH kits, below the reference ranges. However,
those kits with lower detection limits showed more clear cut
senaration of hvoerthvoid oatients and euthyroid subjects.
Among the thyroid function tests, FT3 has been
suggested to be the best test, providing the most accurate
discriminative power for hyperthyroidism (33). In this
study, it was also found that the mean value of FT4 from the
hyperthyroid patients showed the most marked increase in
terms of SD's above reference mean. Theoretically, higher
circulating T3 is expected because in hyperthyroidism, more
T4 is converted to T3. However, this argument has not taken
the looser protein binding and higher clearance rate of T3
into account.
5.2.4 Treated hyperthyroid patient:
The finding that a large percentage of treatec
hyperthyroid patients had suppressed TSH values agrees witi
the findings in other reports (41,66). Although a
significant number of patients also had elevated TT3 or FT;
results, there is no correlation between TSH and TT3 or FT;
indicating that the suppression of TSH was not due to under-
treatment.
A relatively more number of patients with elevated TT3
or FT3 values may be explained by the anti-thyroid drug,
carbimazole, commonly used for the treatment of
hyperthyroidism. This drug, by blocking the process of
iodine organification creates a situation similar to that
which occurs in hypothyroidism, and thereby inducing more
conversion T4 to T3 (3).
5.2.5 Thyroid function testing strategy
This study confirmed that sensitive TSH assay is the
most sensitive thyroid function test in detecting
hyperthyroidism. Although diagnosis cannot be based on a
suppressed TSH value, it is very useful for excluding thyroid
disorders. By using this test as the first—line screening
test in thyroid function testing strategy it has certain
advantages over TT4. However, due to economical and
technical reasons, many people still use TT4 as an initial
test for detecting thyroid disorders. In the TT4 screening
strategy, usually more than 80% of patients are excluded
from further investigations because of a normal TT4 result
and therefore patients requiring expensive tests such as FT4,
FT3 or TSH is usually less than 20%.
However, the TT4 screening strategy suffers from z
number of drawbacks. First, it is difficult to set the lower
or upper limits for further investigation. If the upper
limit is set too low, too many patients will require further
investigation and the strategy will be less cost effective.
If the upper limit is set too high, more hyperthyroic
patients will be missed in the screening. Secondly, no matter
what limits are set, T3-toxicosis, or thyroid diseases
assoicated with thyroxine binding protein abnormalities will
be missed.
Thyroid function testing strategy using sensitive TSH as
the initial screening test will be more reliable in excluding
patients from further investigation. Patients with thyroid
disorders can seldomly be missed. However, at the moment the
cost of a TSH assay is still much higher than a TT4 assay if
an automated EMIT procedure is used. If the TT4 test is
replaced by a sensitive TSH, the financial burden will be
quite enormous. Nevertheless, if the TSH screening strategy
is confined to new thyroid cases, the additional cost will be
justified because patients with thyroid disorders missed in
the TT4 screening may suffer for a long time. When the
disease is discovered later, the condition may have
deteriorated and the medical treatment required may out¬
balance the additional cost used in the thyroid screening
strategy. Therefore, it is proposed that a sensitive TSH may
be used for screening all new cases suspected of thyroid
disorders and abnormal results confirmed by FT4 or FT3,
while the TT4 test is used for other cases.
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